The Evolution of Multidisciplinary Head and Neck Cancer Treatment
The Laryngoscope · 2025-07 · 135 (7) · 2255-2260
DOI: 10.1002/lary.32064 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Laryngoscope, online erschienen am 17.02.2025. Verfasst von Kevin J Contrera und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Head and Neck Neoplasms, Squamous Cell Carcinoma of Head and Neck. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
The management of head and neck squamous cell carcinoma (HNSCC) has substantially changed over the past two centuries. This review explores the historical progression of HNSCC management focusing on the multidisciplinary treatment paradigm. Data Sources This review synthesizes data from historical and current clinical trials, books, scientific reports, public documents, and other written material relevant to HNSCC management. Review Methods Historical review.
Results
Although surgery was initially the only treatment available, radiation, chemotherapy, and immunotherapy have expanded the treatment landscape for HNSCC. Despite continuous evolution, modern treatment of HNSCC remains rooted in a multidisciplinary, personalized approach. This review highlights the clinical pioneers who established the standards of care and the landmark trials that progressed it. The optimal timing, application, and extent of different treatments, including the role of neoadjuvant therapy, remain under study. Immunotherapy has improved outcomes for recurrent/metastatic mucosal HNSCC and cutaneous malignancies, although its role in the curative management of mucosal HNSCC is still materializing.
Conclusions
Surgery and radiotherapy have made continued gains in reducing morbidity and treatment sequala. Platinum‐based chemotherapy remains the mainstay of systemic therapy for HNSCC, but there has been accelerated growth in the application of immunotherapy and targeted therapy. Comprehensive head and neck cancer care depends on multidisciplinary management, usually requiring multiple treatment modalities while individualizing both the therapies and treatment goals. Additional phase III trials are needed to further define the optimal treatments for HNSCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otolaryngology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
- Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
- Department of Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
ORCID-Profile: Kevin J Contrera, Vanessa Helou
Zitieren
APA
Contrera, K. J., Reddy, P. D., Helou, V., Myers, J. N., Skinner, H. D., Ferrarotto, R., & Myers, E. N. (2025). The Evolution of Multidisciplinary Head and Neck Cancer Treatment. The Laryngoscope, 135(7), 2255-2260. https://doi.org/10.1002/lary.32064
Vancouver
Contrera KJ, Reddy PD, Helou V, Myers JN, Skinner HD, Ferrarotto R, et al. The Evolution of Multidisciplinary Head and Neck Cancer Treatment. The Laryngoscope. 2025;135(7):2255-2260. doi:10.1002/lary.32064
BibTeX
@article{Contrera2025,
author = {Contrera, Kevin J and Reddy, Pooja D and Helou, Vanessa and Myers, Jeffrey N and Skinner, Heath D and Ferrarotto, Renata and Myers, Eugene N},
title = {The Evolution of Multidisciplinary Head and Neck Cancer Treatment},
journal = {The Laryngoscope},
year = {2025},
volume = {135},
number = {7},
pages = {2255--2260},
doi = {10.1002/lary.32064}
}
EUVIMED